Potential of mesenchymal- and cardiac progenitor cells for therapeutic targeting of B-cells and antibody responses in end-stage heart failure.

Potential of mesenchymal- and cardiac progenitor cells for therapeutic targeting of B-cells and antibody responses in end-stage heart failure.

Upon myocardial damage, the release of cardiac proteins induces a strong antibody-mediated immune response, which can lead to adverse cardiac remodeling and eventually heart failure (HF). Stem cell therapy using mesenchymal stromal cells (MSCs) or cardiomyocyte progenitor cells (CPCs) previously sho...

Full description

Bibliographic Details
Main Authors: Patricia van den Hoogen, Saskia C A de Jager, Emma A Mol, Arjan S Schoneveld, Manon M H Huibers, Aryan Vink, Pieter A Doevendans, Jon D Laman, Joost P G Sluijter
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0227283

Internet

https://doi.org/10.1371/journal.pone.0227283

Similar Items